Quest Raises 2026 Revenue and EPS Guidance Again

The Tip Desk · October 22, 2026 · 2 min read

Third-quarter revenue reached $3.10 billion, up 10.0%, as Quest lifted full-year net revenue to as much as $12.105 billion.

Quest Diagnostics Incorporated (DGX), a leading provider of diagnostic information services, reported third-quarter net revenues of $3.10 billion, up 10.0% from a year earlier, and raised full-year 2026 revenue and earnings guidance for a third consecutive quarter.

The company now expects full-year 2026 net revenues of $12.065 billion to $12.105 billion, or 9.3% to 9.7% growth, versus prior guidance of $11.95 billion to $12.05 billion, or 8.3% to 9.2% growth. Reported diluted EPS is now expected at $10.21 to $10.31, and adjusted diluted EPS at $11.25 to $11.35. Cash provided by operations is now expected at approximately $1.90 billion, up from about $1.80 billion; capital expenditures remain approximately $550 million.

Chairman, CEO and President Jim Davis said the company delivered 10% revenue growth and adjusted EPS growth of over 15% on continued strength across physician, hospital and consumer channels, complemented by productivity gains from automation and AI. He said the company is raising revenue and EPS guidance for the full year.

Requisition volume rose 14.5% and organic requisition volume rose 14.4%, faster than the 13.1% and 13.0% increases in the second quarter. Revenue per requisition fell 4.2%. Diagnostic Information Services revenues were $3.035 billion.

Reported operating income was $479 million, up 24.2%, and operating income as a percentage of net revenues was 15.5%, up 1.8 percentage points. Adjusted operating income was $517 million, and the adjusted operating margin was 16.7%. Net income attributable to Quest Diagnostics was $312 million. Reported diluted EPS was $2.78, up 28.7%; adjusted diluted EPS was $3.00, up 15.4%.

Cash provided by operations was $611 million. Capital expenditures were $166 million.

The company announced that iPhone and iPad users in the United States can purchase a tailored Quest laboratory test panel with over 50 biomarkers through the Apple Health app, available later this year. It extended AD-Detect to include the FDA-cleared Roche Elecsys Phospho-Tau (217P) Plasma blood test and launched a new AD-Detect panel with pTau217, amyloid beta and APOE.

Quest finalized a definitive agreement to acquire select outreach lab assets from a leading health system and long-time Co-Lab Solutions customer in the Northeastern U.S. It continued to advance Co-Lab Solutions and a joint venture lab with Corewell Health in Michigan. Project Nova moved from the design phase to the solutions-build phase; the company continues to expect to deploy Epic solutions in its first lab in the fall of 2027.

The company will hold its 2027 Investor Day on March 25, 2027, at the New York Stock Exchange.